Evidence map›Paper›PMID 20691741›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2010

Polymer particle shape independently influences binding and internalization by macrophages.

Gaurav Sharma, David T Valenta, Yoav Altman, Sheryl Harvey, Hui Xie, Samir Mitragotri, Jeffrey W Smith

Abstract read
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 124 papers.

0numbers the graph read from it
0cells of the map it votes in
124citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

124 citing papers in PubMed.

  1. Microparticles synthesized from itaconate polyesters enable metabolite delivery and elicit immunoregulatory outcomes.Journal of controlled release : official journal of the Controlled Release Society · 2026
    Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Cell-drug conjugates.Nature biomedical engineering · 2024
    Review
  11. Article
  12. Oxidized mRNA Lipid Nanoparticles forAdvanced functional materials · 2024
    Article
  13. Review
  14. Article
  15. Review
  16. Nanomedicine for Diagnosis and Treatment of Atherosclerosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023
    Review
  17. Review
  18. Review
  19. Review
  20. Review

64 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Gaurav SharmaSanford-Burnham Medical Research Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA.
David T Valenta
Yoav Altman
Sheryl Harvey
Hui Xie
Samir Mitragotri
Jeffrey W Smith

Funding

Nanotherapy for Vulnerable PlaqueU01HL080718 · NHLBI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI SMITH, JEFFREY W · 2005 to 2009
$12.8M
NHLBI NIH HHS HL080718NHLBI NIH HHS U01 HL080718
6 · The paper itself

Abstract

The interaction of macrophages with micro and nanoparticles (MNPs) is important because these cells clear particles from the circulation, and because they are potential therapeutic targets in inflammatory conditions, atherosclerosis and cancer. Therefore, an understanding of the features of MNPs that influence their interaction with macrophages may allow optimization of their properties for enhanced drug delivery. In this study, we show that particle shape impacts phagocytosis by macrophages, and more importantly, that particle shape and size separately impact attachment and internalization. The study provides a methodology for further exploring how particle shape can be controlled to achieve desired attachment and internalization. The results of the study also give mechanistic guidance on how particle shape can be manipulated to design drug carriers to evade macrophages, or alternatively to target macrophages.

Indexed as

Drug CarriersNanoparticlesPhagocytosisAnimalsCell LineCell MembraneFlow CytometryMacrophagesMiceMicroscopy, ConfocalParticle SizePolystyrenesSurface PropertiesTechnology, PharmaceuticalTime FactorsDrug CarriersPolystyrenes

Identifiers

PMID20691741
PMCPMC2975856

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.